Apollomics (APLM) News Today $0.15 -0.01 (-6.26%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Apollomics, Inc. (NASDAQ:APLM) Sees Significant Drop in Short InterestNovember 14, 2024 | americanbankingnews.comHyloris Pharmaceuticals SA (52U.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comApollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comFlutter in talks to buy Italy's Snaitech for $2.6B, Sky News reportsAugust 14, 2024 | uk.finance.yahoo.comApollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressAugust 14, 2024 | globenewswire.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataAugust 13, 2024 | msn.comApollomics stock rallies 30% on Phase 2 vebreltinib dataAugust 13, 2024 | msn.comApollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialAugust 13, 2024 | globenewswire.comApollomics to Present at the Canaccord Genuity 44th Annual Growth ConferenceAugust 9, 2024 | finance.yahoo.comWhat's Going On With Apollomics (APLM) Stock Exploding Higher?July 19, 2024 | benzinga.comApollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementJuly 16, 2024 | globenewswire.comApollomics Announces Updated Strategic Focus and Leadership Team ChangesJuly 3, 2024 | globenewswire.comApollomics Announces Presentation at the 2024 BIO International ConventionMay 29, 2024 | finance.yahoo.comMaintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline PotentialMay 8, 2024 | markets.businessinsider.comApollomics Announces Private Placement Financing and Addition to Board of DirectorsMay 8, 2024 | finance.yahoo.comApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneApril 25, 2024 | globenewswire.comApollomics (APLM) Price Target Decreased by 58.93% to 5.87April 17, 2024 | msn.comApollomics, Inc. (APLM) Interactive Stock Chart - Yahoo FinanceApril 16, 2024 | finance.yahoo.comApollomics, Inc. (NASDAQ:APLM) Sees Large Increase in Short InterestApollomics, Inc. (NASDAQ:APLM - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 155,100 shares, a growth of 238.6% from the March 15th total of 45,800 shares. Based on an average daily trading volume, of 216,000 shares, the short-interest ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are sold short.April 10, 2024 | marketbeat.comApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 10, 2024 | globenewswire.comQ1 2024 EPS Estimates for Apollomics, Inc. Decreased by Analyst (NASDAQ:APLM)Apollomics, Inc. (NASDAQ:APLM - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2024 earnings per share (EPS) estimates for Apollomics in a report released on Monday, April 1st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.17) per share forApril 3, 2024 | marketbeat.comApollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 2, 2024 | finance.yahoo.comHC Wainwright Trims Apollomics (NASDAQ:APLM) Target Price to $5.00HC Wainwright reduced their price objective on shares of Apollomics from $17.00 to $5.00 and set a "buy" rating for the company in a research report on Monday.April 1, 2024 | marketbeat.comApollomics GAAP EPS of -$2.32March 28, 2024 | msn.comApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comApollomics (APLM) Set to Announce Quarterly Earnings on ThursdayApollomics (NASDAQ:APLM) will be releasing earnings before the market opens on Thursday, March 28, Zacks reports.March 27, 2024 | marketbeat.comApollomics Names Matthew Plunkett as Chief Financial OfficerMarch 4, 2024 | finance.yahoo.comApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerMarch 4, 2024 | globenewswire.comApollomics Stock (NASDAQ:APLM), Short Interest ReportFebruary 22, 2024 | benzinga.comShort Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 54.5%Apollomics, Inc. (NASDAQ:APLM - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 63,900 shares, a drop of 54.5% from the January 15th total of 140,500 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 1,980,000 shares, the days-to-cover ratio is presently 0.0 days.February 12, 2024 | marketbeat.comApollomics (NASDAQ:APLM) Stock Price Down 1.2%Apollomics (NASDAQ:APLM) Shares Down 1.2%February 3, 2024 | marketbeat.comApollomics Inc.: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 20, 2024 | finanznachrichten.deApollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 19, 2024 | finance.yahoo.comApollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology ConferenceJanuary 17, 2024 | stockhouse.comApollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia TreatmentJanuary 3, 2024 | finance.yahoo.comApollomics Inc Ordinary Shares - Class A APLMDecember 17, 2023 | morningstar.comApollomics Inc Ordinary Shares - Class ADecember 12, 2023 | morningstar.comApollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer MedicationDecember 7, 2023 | finance.yahoo.comApollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationDecember 4, 2023 | finance.yahoo.comApollomics, Inc. (APLM)November 28, 2023 | ca.finance.yahoo.comApollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)November 28, 2023 | finance.yahoo.comApollomics Shares More Than Double on Partner's Approval for Commercialization of VebreltinibNovember 16, 2023 | marketwatch.comWhy Is Cancer Firm Apollomics Stock Trading Higher Today?November 16, 2023 | msn.comApollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNovember 16, 2023 | finance.yahoo.comApollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationOctober 31, 2023 | finance.yahoo.comApollomics stock soars 76% following positive report for brain cancer therapyOctober 27, 2023 | msn.comWhat's Going On With Apollomics Inc Stock?October 27, 2023 | benzinga.comTrading was temporarily halted for "APLM" at 09:10 AM with a stated reason of "LULD pause."October 27, 2023 | marketbeat.comWhy Is Apollomics (APLM) Stock Up 113% Today?October 27, 2023 | investorplace.comApollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionOctober 26, 2023 | finance.yahoo.com Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. APLM Media Mentions By Week APLM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLM News Sentiment▼-0.250.45▲Average Medical News Sentiment APLM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLM Articles This Week▼10▲APLM Articles Average Week Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Leap Therapeutics News Today CytomX Therapeutics News Today BeyondSpring News Today Cellectar Biosciences News Today Celularity News Today ALX Oncology News Today Immuneering News Today Spero Therapeutics News Today InterCure News Today CervoMed News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
